Cargando…
P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429120/ http://dx.doi.org/10.1097/01.HS9.0000846928.64504.71 |
| _version_ | 1784779336812855296 |
|---|---|
| author | Reiter, A. Gotlib, J. Álvarez-Twose, I. Radia, D. H. Luebke, J. Bobbili, P. J. Wang, A. Norregaard, C. Dimitrijević, S. Sullivan, E. Louie-Gao, M. Schwaab, J. Galinsky, I. A. Perkins, C. Sperr, W. R. Sriskandarajah, P. Chin, A. Sendhil, S. R. Duh, M. S. Valent, P. DeAngelo, D. J. |
| author_facet | Reiter, A. Gotlib, J. Álvarez-Twose, I. Radia, D. H. Luebke, J. Bobbili, P. J. Wang, A. Norregaard, C. Dimitrijević, S. Sullivan, E. Louie-Gao, M. Schwaab, J. Galinsky, I. A. Perkins, C. Sperr, W. R. Sriskandarajah, P. Chin, A. Sendhil, S. R. Duh, M. S. Valent, P. DeAngelo, D. J. |
| author_sort | Reiter, A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429120 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94291202022-08-31 P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY Reiter, A. Gotlib, J. Álvarez-Twose, I. Radia, D. H. Luebke, J. Bobbili, P. J. Wang, A. Norregaard, C. Dimitrijević, S. Sullivan, E. Louie-Gao, M. Schwaab, J. Galinsky, I. A. Perkins, C. Sperr, W. R. Sriskandarajah, P. Chin, A. Sendhil, S. R. Duh, M. S. Valent, P. DeAngelo, D. J. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429120/ http://dx.doi.org/10.1097/01.HS9.0000846928.64504.71 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Reiter, A. Gotlib, J. Álvarez-Twose, I. Radia, D. H. Luebke, J. Bobbili, P. J. Wang, A. Norregaard, C. Dimitrijević, S. Sullivan, E. Louie-Gao, M. Schwaab, J. Galinsky, I. A. Perkins, C. Sperr, W. R. Sriskandarajah, P. Chin, A. Sendhil, S. R. Duh, M. S. Valent, P. DeAngelo, D. J. P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY |
| title | P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY |
| title_full | P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY |
| title_fullStr | P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY |
| title_full_unstemmed | P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY |
| title_short | P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY |
| title_sort | p1015: duration of treatment and reduction in serum tryptase levels in patients with advanced systemic mastocytosis treated with avapritinib versus best available therapy |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429120/ http://dx.doi.org/10.1097/01.HS9.0000846928.64504.71 |
| work_keys_str_mv | AT reitera p1015durationoftreatmentandreductioninserumtryptaselevelsinpatientswithadvancedsystemicmastocytosistreatedwithavapritinibversusbestavailabletherapy AT gotlibj p1015durationoftreatmentandreductioninserumtryptaselevelsinpatientswithadvancedsystemicmastocytosistreatedwithavapritinibversusbestavailabletherapy AT alvareztwosei p1015durationoftreatmentandreductioninserumtryptaselevelsinpatientswithadvancedsystemicmastocytosistreatedwithavapritinibversusbestavailabletherapy AT radiadh p1015durationoftreatmentandreductioninserumtryptaselevelsinpatientswithadvancedsystemicmastocytosistreatedwithavapritinibversusbestavailabletherapy AT luebkej p1015durationoftreatmentandreductioninserumtryptaselevelsinpatientswithadvancedsystemicmastocytosistreatedwithavapritinibversusbestavailabletherapy AT bobbilipj p1015durationoftreatmentandreductioninserumtryptaselevelsinpatientswithadvancedsystemicmastocytosistreatedwithavapritinibversusbestavailabletherapy AT wanga p1015durationoftreatmentandreductioninserumtryptaselevelsinpatientswithadvancedsystemicmastocytosistreatedwithavapritinibversusbestavailabletherapy AT norregaardc p1015durationoftreatmentandreductioninserumtryptaselevelsinpatientswithadvancedsystemicmastocytosistreatedwithavapritinibversusbestavailabletherapy AT dimitrijevics p1015durationoftreatmentandreductioninserumtryptaselevelsinpatientswithadvancedsystemicmastocytosistreatedwithavapritinibversusbestavailabletherapy AT sullivane p1015durationoftreatmentandreductioninserumtryptaselevelsinpatientswithadvancedsystemicmastocytosistreatedwithavapritinibversusbestavailabletherapy AT louiegaom p1015durationoftreatmentandreductioninserumtryptaselevelsinpatientswithadvancedsystemicmastocytosistreatedwithavapritinibversusbestavailabletherapy AT schwaabj p1015durationoftreatmentandreductioninserumtryptaselevelsinpatientswithadvancedsystemicmastocytosistreatedwithavapritinibversusbestavailabletherapy AT galinskyia p1015durationoftreatmentandreductioninserumtryptaselevelsinpatientswithadvancedsystemicmastocytosistreatedwithavapritinibversusbestavailabletherapy AT perkinsc p1015durationoftreatmentandreductioninserumtryptaselevelsinpatientswithadvancedsystemicmastocytosistreatedwithavapritinibversusbestavailabletherapy AT sperrwr p1015durationoftreatmentandreductioninserumtryptaselevelsinpatientswithadvancedsystemicmastocytosistreatedwithavapritinibversusbestavailabletherapy AT sriskandarajahp p1015durationoftreatmentandreductioninserumtryptaselevelsinpatientswithadvancedsystemicmastocytosistreatedwithavapritinibversusbestavailabletherapy AT china p1015durationoftreatmentandreductioninserumtryptaselevelsinpatientswithadvancedsystemicmastocytosistreatedwithavapritinibversusbestavailabletherapy AT sendhilsr p1015durationoftreatmentandreductioninserumtryptaselevelsinpatientswithadvancedsystemicmastocytosistreatedwithavapritinibversusbestavailabletherapy AT duhms p1015durationoftreatmentandreductioninserumtryptaselevelsinpatientswithadvancedsystemicmastocytosistreatedwithavapritinibversusbestavailabletherapy AT valentp p1015durationoftreatmentandreductioninserumtryptaselevelsinpatientswithadvancedsystemicmastocytosistreatedwithavapritinibversusbestavailabletherapy AT deangelodj p1015durationoftreatmentandreductioninserumtryptaselevelsinpatientswithadvancedsystemicmastocytosistreatedwithavapritinibversusbestavailabletherapy |